BIM
114.2
+0.79%↑
SRT3
229.2
+0.26%↑
GXI
54
+3.75%↑
ICAD
21.06
-1.5%↓
BIM
114.2
+0.79%↑
SRT3
229.2
+0.26%↑
GXI
54
+3.75%↑
ICAD
21.06
-1.5%↓
BIM
114.2
+0.79%↑
SRT3
229.2
+0.26%↑
GXI
54
+3.75%↑
ICAD
21.06
-1.5%↓
BIM
114.2
+0.79%↑
SRT3
229.2
+0.26%↑
GXI
54
+3.75%↑
ICAD
21.06
-1.5%↓
BIM
114.2
+0.79%↑
SRT3
229.2
+0.26%↑
GXI
54
+3.75%↑
ICAD
21.06
-1.5%↓
24h
Šī brīža
Min
118.85
Max
122.35
Ienākumi | -142M 667M |
---|---|
Pārdošana | 152M 5.4B |
P/E Sektora vidējais | 26.27 57.333 |
EPS | 2.2 |
Dividenžu ienesīgums | 1.34 |
Peļņas marža | 12.311 |
EBITDA | 85M 1.6B |
Rekomendācijas | Pirkt |
---|---|
Prognoze 12 mēnešiem | +37.85% upside |
Dividenžu ienesīgums Sektora vidējais | 1.34% 2.63% |
---|---|
Nākamie ieņēmumi | 2025. g. 15. maijs |
Tirgus kapitalizācija | 33B 98B |
---|---|
Iepriekšējā atvēršanas cena | 119.76 |
Iepriekšējā slēgšanas cena | 120.35 |
By Trading Central
Pārliecība
Very Strong Bullish Evidence
117.55 / N/A Atbalsts un pretestība
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
2025. g. 6. marts 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Lasīt
2025. g. 11. febr. 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Lasīt
2025. g. 10. febr. 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Lasīt
2025. g. 24. apr. 22:51 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update
DJ
Lasīt
2025. g. 24. apr. 20:54 UTC
Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into
DJ
Lasīt
2025. g. 24. apr. 20:50 UTC
Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share
DJ
Lasīt
2025. g. 24. apr. 19:05 UTC
Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ
DJ
Lasīt
2025. g. 24. apr. 19:05 UTC
Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ
DJ
Lasīt
2025. g. 24. apr. 19:05 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ
DJ
Lasīt
2025. g. 24. apr. 19:05 UTC
Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ
DJ
Lasīt
2025. g. 6. marts 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Lasīt
2025. g. 6. marts 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Lasīt
2025. g. 6. marts 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Lasīt
2025. g. 6. marts 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Lasīt
2025. g. 11. febr. 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Lasīt
2025. g. 11. febr. 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Lasīt
2025. g. 11. febr. 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Lasīt
2025. g. 6. janv. 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Lasīt
2025. g. 6. janv. 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Lasīt
2025. g. 6. janv. 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Lasīt
Cenas izmaiņa
By TipRanks
Prognoze 12 mēnešiem
Vidējais 166.25 EUR 37.85%
Augstākais 190 EUR
Zemākais 107 EUR
Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merck KGaA — pēdējo 3 mēnešu laikā.
By TipRanks
Pirkt
9 ratings
6
Pirkt
2
Turēt
1
Pārdot
Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Merck KGaA — pēdējo 3 mēnešu laikā.
By Trading Central
Īstermiņā
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Vidējā termiņā
Bearish Evidence
All events are bearish.
Ilgtermiņā
Bearish Evidence
All events are bearish.
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$